✦ LIBER ✦

9136 Erlotinib as a second-line therapy in advanced non small cell lung cancer: correlation between clinical characteristics and biomarkers

✍ Scribed by Rotella, V.; Mazzoni, F.; Pratesi, N.; Simi, L.; Orlando, C.; Boni, L.; Comin, C.E.; Maddau, C.; Costanzo, F. Di

Book ID: 122999351
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 47 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71849-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Phase III Trial of Erlotinib

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

✍ Kawaguchi, T.; Ando, M.; Asami, K.; Okano, Y.; Fukuda, M.; Nakagawa, H.; Ibata, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 183 KB

P-500 Weekly docetaxel and vinorelbine a

P-500 Weekly docetaxel and vinorelbine as second-line therapy in advanced non-small cell lung cancer

✍ Huber, R.; Schmidt, M.; Borgmeier, A. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Docetaxel and mitomycin as second-line t

Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer

✍ J. Feliu; G. Martín; J. Castro; A. Sundlov; A. Rodriguez-Jaráiz; E. Casado; M. L 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 209 KB

90P ERLOTINIB VS CHEMOTHERAPY AS SECOND

90P ERLOTINIB VS CHEMOTHERAPY AS SECOND LINE THERAPY FOR PATIENTS WITH ADVANCED EGFRWT NON SMALL CELL LUNG CANCER. A SINGLE INSTITUTION EXPERIENCE

✍ Garde, J.; García, J.; Berzosa, M.; Marin, S.; Sangrador, C.; Piera, N.; Hidalgo 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Second-Line Therapy in Non-Small-Cell Lu

Second-Line Therapy in Non-Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens

✍ Zer, A.; Leighl, N. B. 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 133 KB

First-Line Erlotinib Followed by Second-

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial

✍ Gridelli, C.; Ciardiello, F.; Gallo, C.; Feld, R.; Butts, C.; Gebbia, V.; Maione 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 259 KB